Safinamide in the treatment of Parkinson's disease

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 13, 2010, Pages 2261-2268

  Schapira, Anthony Hv ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Monoamine oxidase; Neuroprotection; Parkinson's disease; Safinamide

Indexed keywords

AMANTADINE; CARBIDOPA PLUS ENTACAPONE PLUS LEVODOPA; DIZOCILPINE; DOPAMINE; ENTACAPONE; LEVODOPA; OXIDOPAMINE; PLACEBO; PRAMIPEXOLE; RASAGILINE; ROPINIROLE; ROTIGOTINE; SAFINAMIDE; SELEGILINE; VERATRIDINE;

BEHAVIOR CHANGE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG STRUCTURE; DRUG TOLERABILITY; DYSKINESIA; HEALTH SURVEY; HUMAN; IMPULSE CONTROL DISORDER; LEG EDEMA; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; NEURON TOXICITY; NEUROPROTECTION; PARKINSON DISEASE; PATHOGENESIS; REVIEW; SIDE EFFECT;

ALANINE; ANIMALS; ANTIPARKINSON AGENTS; BENZYLAMINES; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; HUMANS; PARKINSON DISEASE; TREATMENT OUTCOME;

EID: 77955832709     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2010.511612     Document Type: Review

References (89)

1. Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinsons disease: dopaminergic pathophysiology and treatment. Lancet Neurol 2009;8:464-474
2. Chaudhuri KR, Healy DG, Schapira AH. Non-motor symptoms of Parkinsons disease: diagnosis and management. Lancet Neurol 2006;5:235-245
3. Tolosa E, Wenning G, Poewe W. The diagnosis of Parkinsons disease. Lancet Neurol 2006;5:75-86
4. Mylne AQ, Griffiths C, Rooney C, Doyle P. Trends in Parkinsons disease related mortality in England and Wales, 1993-2006. Eur J Neurol 2009;16:1010-1016
5. Haberfeld E, Louis ED. Is Parkinsons disease-related mortality declining? Eur J Neurol 2009;16:964-965
6. Zhao YJ, Tan LC, Lau PN, et al. Factors affecting health-related quality of life amongst Asian patients with Parkinsons disease. Eur J Neurol 2008;15:737-742
7. Lim SY, Fox SH, Lang AE. Overview of the extranigral aspects of Parkinson disease. Arch Neurol 2009;66:167-172
8. Bachmann CG, Zapf A, Brunner E, Trenkwalder C. Dopaminergic treatment is associated with decreased body weight in patients with Parkinsons disease and dyskinesias. Eur J Neurol 2009;16:895-901
9. Imamura A, Geda YE, Slowinski J, et al. Medications used to treat Parkinsons disease and the risk of gambling. Eur J Neurol 2008;15:350-354
10. Halbig TD, Tse W, Frisina PG, et al. Subthalamic deep brain stimulation and impulse control in Parkinsons disease. Eur J Neurol 2009;16:493-497
11. Schapira AH. Excessive daytime sleepiness in Parkinsons disease. Neurology 2004;63(Suppl 3):S24-7
12. Schapira AH. The scientific and clinical basis for future therapies in Parkinsons disease. Eur J Neurol 2008;15(Suppl 1):v
13. Fox SH, Brotchie JM, Lang AE. Non-dopaminergic treatments in development for Parkinsons disease. Lancet Neurol 2008;7:927-938
14. Elgh E, Domellof M, Linder J, et al. Cognitive function in early Parkinsons disease: a population-based study. Eur J Neurol 2009;16:1278-1284
15. Reyes MA, Lloret SP, Gerscovich ER, et al. Addenbrookes cognitive examination validation in Parkinsons disease. Eur J Neurol 2009;16:142-147
16. Klepac N, Trkulja V, Relja M, Babic T. Is quality of life in non-demented Parkinsons disease patients related to cognitive performance? A clinic-based cross-sectional study. Eur J Neurol 2008;15:128-133
17. Koerts J, Leenders KL, Koning M, et al. The assessment of depression in Parkinsons disease. Eur J Neurol 2008;15:487-492
18. Antonini A. Unraveling depression in Parkinsons disease. Eur J Neurol 2008;15:885-886
19. Matinolli M, Korpelainen JT, Korpelainen R, et al. Mobility and balance in Parkinsons disease: a population-based study. Eur J Neurol 2009;16:105-111
20. Benito-Leon J, Louis ED, Bermejo-Pareja F. Population-based case-control study of morale in Parkinsons disease. Eur J Neurol 2009;16:330-336
21. Vossius C, Nilsen OB, Larsen JP. Parkinsons disease and nursing home placement: the economic impact of the need for care. Eur J Neurol 2009;16:194-200
22. Onofrj M, Bonanni L, Thomas A. An expert opinion on safinamide in Parkinsons disease. Expert Opin Investig Drugs 2008;17:1115-1125
23. Binda C, Wang J, Pisani L, et al. Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs. J Med Chem 2007;50:5848-5852
24. Marzo A, Dal Bo L, Monti NC, et al. Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity. Pharmacol Res 2004;50:77-85
25. Caccia C, Salvati P, Rossetti S, Anand R. Safinamide: modulation of dopaminergic and glutamatergic systems. Mov Disord 2008;67:S22-3
26. Chazot PL. Drug evaluation: safinamide for the treatment of Parkinsons disease, epilepsy and restless legs syndrome. Curr Opin Investig Drugs 2007;8:570-579
27. Caccia C, Maj R, Calabresi M, et al. Safinamide: from molecular targets to a new anti-Parkinson drug. Neurology 2006;67(Suppl 2):S18-23
28. Leonetti F, Capaldi C, Pisani L, et al. Solid-phase synthesis and insights into structure-activity relationships of safinamide analogues as potent and selective inhibitors of type B monoamine oxidase. J Med Chem 2007;50:4909-4916
29. Schapira AH, Agid Y, Barone P, et al. Perspectives on recent advances in the understanding and treatment of Parkinsons disease. Eur J Neurol 2009;16:1090-1099
30. Schapira AH. Molecular and clinical pathways to neuroprotection of dopaminergic drugs in Parkinson disease. Neurology 2009;72(Suppl):S44-50
31. Olanow CW, Kieburtz K, Schapira AH. Why have we failed to achieve neuroprotection in Parkinsons disease? Ann Neurol 2008;64(Suppl 2):S101-10
32. Finkbeiner S, Cuervo AM, Morimoto RI, Muchowski PJ. Disease-modifying pathways in neurodegeneration. J Neurosci 2006;26:10349-10357
33. Schapira AH. Neurobiology and treatment of Parkinsons disease. Trends Pharm Sci 2009;30:41-47
34. Schapira AHV. Etiology of Parkinsons disease. Neurology 2006;66:S10-23
35. Lesage S, Brice A. Parkinsons disease: from monogenic forms to genetic susceptibility factors. Hum Mol Genet 2009;18(R1):R48-59
36. Tan EK, Schapira AH. Uniting Chinese across Asia: the LRRK2 Gly2385Arg risk variant. Eur J Neurol 2008;15:203-204
37. Elbaz A, Clavel J, Rathouz PJ, et al. Professional exposure to pesticides and Parkinson disease. Ann Neurol 2009;66:494-504
38. Richardson JR, Shalat SL, Buckley B, et al. Elevated serum pesticide levels and risk of Parkinson disease. Arch Neurol 2009;66:870-875
39. Healy DG, Falchi M, Osullivan SS, et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinsons disease: a case-control study. Lancet Neurol 2008;7:583-590
40. Pchelina SN, Yakimovskii AF, Emelyanov AK, et al. Screening for LRRK2 mutations in patients with Parkinsons disease in Russia: identification of a novel LRRK2 variant. Eur J Neurol 2008;15:692-696
41. An XK, Peng R, Li T, et al. LRRK2 Gly2385Arg variant is a risk factor of Parkinsons disease among Han-Chinese from mainland China. Eur J Neurol 2008;15:301-305
42. Schapira AH. Mitochondria in the aetiology and pathogenesis of Parkinsons disease. Lancet Neurol 2008;71:97-109
43. Thomas B, Beal MF. Parkinsons disease. Hum Mol Genet 2007;16:R183-94
44. Schapira AH. Complex I: inhibitors, inhibition and neurodegeneration. Exp Neurol 2010;224:331-335
45. Owen AD, Schapira AH, Jenner P, Marsden CD. Oxidative stress and Parkinsons disease. Ann N Y Acad Sci 1996;786:217-223
46. Alvarez-Erviti L, Rodriguez-Oroz MC, Cooper JM, et al. Chaperone-mediated autophagy markers are abnormal in Parkinsons disease brain. Arch Neurol 2010; In press
47. Schapira AH. Future directions in the treatment of Parkinsons disease. Mov Disord 2007;22(Suppl 17):S385-91
48. Schapira AH, Bezard E, Brotchie J, et al. Novel pharmacological targets for the treatment of Parkinsons disease. Nat Rev Drug Discov 2006;5:845-854
49. Schapira AH. Science, medicine, and the future: Parkinsons disease. BMJ 1999;318:311-314
50. LeWitt PA. Clinical trials of neuroprotection for Parkinsons disease. Neurology 2004;63(Suppl 2):S23-31
51. Rascol O. Disease-modification trials in Parkinson disease: target populations, endpoints and study design. Neurology 2009;72(Suppl):S51-8
52. Schapira AH. Progress in neuroprotection in Parkinsons disease. Eur J Neurol 2008;15(Suppl 1):5-13
53. Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinsons disease. N Engl J Med 2009;361:1268-1278
54. Stocchi F, Arnold G, Onofrj M, et al. Improvement of motor function in early Parkinson disease by safinamide. Neurology 2004;63:746-748
55. Stocchi F, Vacca L, Grassini P, et al. Symptom relief in Parkinson disease by safinamide: biochemical and clinical evidence of efficacy beyond MAO-B inhibition. Neurology 2006;67(Suppl 2):S24-9
56. Sharma T, Stocchi F, Schapira AH, et al. Safinamide treatment improves cognition in Parkinsons disease. Mov Disord 2007;22:29
57. Borgohain R, Szasz J, Bhatt M, et al. Efficacy and safety of safinamide in patients with Parkinsons disease experiencing motor fluctuations: results of a 6-month Phase III, randomized, double-blind, placebo-controlled study. 2009. Available from: http://www. movementdisorders.org/congress/congress09/late- breaking-abstracts.pdf
58. Stocchi F, Borgohain R, Onofrj M, et al. Safinamide, a new anti-Parkinson agent is effective and well-tolerated in early PD patients on a stable dose of a single DA-agonist: results of a randomized, international, placebo-controlled, phase III trial. Neurology 2007;68:A109
59. Schapira AHV, Borgohain R, Stocchi F, et al. Long-term safety and efficacy of safinamide added to dopamine agonists in early Parkinsons disease (PD). Neurology 2008;70:A424
60. Borgohain R, Bhatt M, Rossetti S, Anand R. Safinamide potentiates the effects of dopamine (DA)-agonists in early stage Parkinsons disease patients. Parkinsonism Relat Disord 2007;13:S99-99
61. Goetz CG, Poewe W, Rascol O, Sampaio C. Evidence-based medical review update: pharmacological and surgical treatments of Parkinsons disease: 2001 to 2004. Mov Disord 2005;20:523-539
62. Pahwa R, Factor SA, Lyons KE, et al. Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006;66:983-995
63. Stewart DA. NICE guideline for Parkinsons disease. Age Ageing 2007;36:240-242
64. Schapira AH, Olanow CW. Drug selection and timing of initiation of treatment in early Parkinsons disease. Ann Neurol 2008;64(Suppl 2):S47-55
65. Schapira AH. Treatment options in the modern management of Parkinson disease. Arch Neurol 2007;64:1083-1088
66. Schapira AH, Emre M, Jenner P, Poewe W. Levodopa in the treatment of Parkinsons disease. Eur J Neurol 2009;16:982-989
67. Mena MA, Davila V, Sulzer D. Neurotrophic effects of L-DOPA in postnatal midbrain dopamine neuron/cortical astrocyte cocultures. J Neurochem 1997;69:1398-1408
68. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinsons disease. N Engl J Med 2004;351:2498-2508
69. Nissinen H, Kuoppamaki M, Leinonen M, Schapira AH. Early versus delayed initiation of entacapone in levodopa-treated patients with Parkinsons disease: a long-term, retrospective analysis. Eur J Neurol 2009;16:1305-1311
70. Bet L, Bareggi SR, Pacei F, et al. Bimodal administration of entacapone in Parkinsons disease patients improves motor control. Eur J Neurol 2008;15:268-273
71. Antonini A, Tolosa E, Mizuno Y, et al. A reassessment of risks and benefits of dopamine agonists in Parkinsons disease. Lancet Neurol 2009;8:929-937
72. Baker WL, Silver D, White CM, et al. Dopamine agonists in the treatment of early Parkinsons disease: a meta-analysis. Parkinsonism Relat Disord 2009;15:287-294
73. Bhattacharyya S, Schapira AH, Mikhailidis DP, Davar J. Drug-induced fibrotic valvular heart disease. Lancet 2009;374:577-585
74. Parkinson Disease Study Group. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease. Arch Neurol 2009;66:563-570
75. Hauser RA, Rascol O, Korczyn AD, et al. Ten-year follow-up of Parkinsons disease patients randomized to initial therapy with ropinirole or levodopa. Mov Disord 2007;22:2409-2417
76. Katzenschlager R, Head J, Schrag A, et al. Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. Neurology 2008;71:474-480
77. Pahwa R, Stacy MA, Factor SA, et al. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology 2007;68:1108-1115
78. Stocchi F, Hunter B, Giorgi L, Schapira AHV. Adjunctive ropinirole 24-hour prolonged release compared with ropinirole immediate release in patients with advanced Parkinsons disease (PD): the PREPARED study. Eur J Neurol 2008;15:134
79. Giladi N, Boroojerdi B, Korczyn AD, et al. Rotigotine transdermal patch in early Parkinsons disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Mov Disord 2007;22:2398-2404
80. Schapira A, Barone P, Hauser RA, et al. Efficacy and safety of pramipexole extended-release for advanced Parkinsons disease. Mov Disord 2009;24:S277-8
81. Poewe W, Barone P, Hauser RA, et al. Pramipexole extended-release is effective in early Parkinsons disease. Mov Disord 2009;24:S273
82. Schapira AH. Dopamine agonists and neuroprotection in Parkinsons disease. Eur J Neurol 2002;9(Suppl 3):7-14
83. Schapira AHV, Hsu HH, Scrine K, et al. PROUD: the impact of early vs. delayed treatment with pramipexole on new onset Parkinsons disease. Eur J Neurol 2008;15:132
84. Parkinson Disease Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 2004;61:561-566
85. Parkinson Disease Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol 2002;59:1937-1943
86. Rascol O, Brooks DJ, Melamed E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinsons disease and motor fluctuations (LARGO, lasting effect in adjunct therapy with rasagiline given once daily, study): a randomised, double-blind, parallel-group trial. Lancet 2005;365:947-954
87. Parkinson Disease Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 2005;62:241-248
88. Schapira AH. Movement disorders: advances in cause and treatment. Lancet Neurol 2010;9:6-7
89. Schapira AHV, Obeso J. Timing of treatment initiation in Parkinsons disease: a need for reappraisal? Ann Neurol 2006;59:559-562